Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
Sharing and utilizing health data for AI—a new report and recommendations for HHS – fedscoop
The Office of the Chief Technology Officer in the U.S. Department of Health and Human Services (HHS) and the Center for Open Data Enterprise (CODE) recently hosted a 70-expert roundtable to gather input from stakeholders on developing an artificial intelligence (AI) strategy for HHS. CODE’s report outlines five categories of AI applications in health care and provides six high-level recommendations to advance the use of this technology.
Read the full article by Katarina Rebello and Paul Kuhne
Hong Kong helps speed up development of new treatments as number of clinical trials in city surges – South China Morning Post
The city of Hong Kong is helping speed up the registration of new pharmaceuticals and therapies globally. Now that the China Food and Drug Administration officially recognizes trial results from Hong Kong, the centers at the University of Hong Kong and Chinese University have witnessed dramatic increases in Phase 1 clinical trials. Billy SK Wong has the full story here
Committed to clarity: FDA’s dedication to transparency with the end of ASR – Mondaq
The U.S. Food and Drug Administration (FDA) released a report that describes the agency’s updates to its Medical Device Reporting (MDR) Program and the conclusion of the Alterative Summary Reporting (ASR) Program. Through this program, companies were able to submit to the FDA quarterly summary reports for well-known adverse events – but very few of these reports were publicly available. In an effort to increase transparency, the FDA released 6 million ASR reports that were previously undisclosed.
Read the article on Mondaq
